drugset / Trial / NCT06612580
68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-NI-093 PET/CT in patients with prostate cancer.
Timeline
- Start
- 2024-09-01
- Primary completion
- 2025-08-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-AAZTA-NI-093 | Unknown | 111 mbq | Intravenous |
| Subject | 68Ga-AAZTA-NI-093 | Unknown | 148 mbq | Intravenous |